中恒集团20240604

Key Points Company Overview - Industry: Pharmaceutical manufacturing and health consumption - Established: 1993 - Listing: Listed on the Shanghai Stock Exchange in April 2000 - Parent Company: Guangxi Investment Group Co., Ltd., a Fortune 500 company - Awards: Top 100 Chinese Medicine Enterprises, Top 100 Chinese Traditional Medicine Enterprises, National Advanced Manufacturing and Modern Service Integration Pilot Enterprise - Main Business: Medicine manufacturing, health consumption, pharmaceutical research and development, traditional Chinese medicine resources, daily chemicals and cosmetics, pharmaceutical distribution - Subsidiaries: Wuzhou Pharmaceutical, Shuangquan Industry, Qianye Chemical Industry Financial Highlights - Revenue: 30.97 billion yuan, up 14.10% YoY - Net Profit: 84.30.88 million yuan, up 6.69% YoY - Operating Cash Flow: 4.03 billion yuan, up 336.95% YoY - Gross Margin: 61.45%, up 2.02 percentage points YoY - Q1 2024 Revenue: 8.06 billion yuan, up 20.34% YoY - Q1 2024 Net Profit: 54.71.12 million yuan, up 419.63% YoY Business Performance - Pharmaceuticals: Revenue of 26.22 billion yuan, up 12.0% YoY - Thrombolytic: Revenue of 12.24 billion yuan, up 33.66% YoY - General Medicines: 29 products in production and sales, 11 products obtained approval - Chemical Medicines:卡拉琳 maintains leading position in the field, new products introduced - Health Consumption: Revenue of 2.40 billion yuan, up 27.29% YoY - Guilinggao: Revenue of 1.93 billion yuan, up 12.44% YoY - Daily Chemicals and Cosmetics: Revenue of 7640.95 million yuan, up 25.91% YoY Strategic Initiatives - Establishment of Zhongheng Yixing Science and Technology Investment Co., Ltd.: Focus on fund investment, equity investment, and asset securitization - Transformation of Guangxi Wuzhou Shuangquan Industrial Co., Ltd.: Renamed to Guangxi Shuangquan Health Industry Co., Ltd. - Completion of Qianye Chemical Industry's asset transfer: Transition to light asset operation - Increased R&D investment: 1.67 billion yuan, up 7.06% YoY - Collaboration with Shanghai Institute of Materia Medica: Achieved four leading-level results in thrombolytic research - Patent authorization: 10 patents authorized, including 7 invention patents - Expert consensus: Injection of desmethylstreptozocin included in the Chinese expert consensus for glioma chemotherapy - Drug approval: Six varieties of Lisumei Pharmaceutical obtained approval, including taxanes and telmisartan tablets Shareholder Returns - Dividend distribution: 34.51.49 million yuan, accounting for 40.94% of net profit - Shareholder return activities: Regularly held through WeChat official account and product carrier Future Outlook - Strengthening the pharmaceutical sector: Focus on traditional Chinese medicine, chemical medicine, and biopharmaceuticals - Expanding the health consumption sector: Introduce capital investment, innovate products, and strengthen brand output - Driving high-quality development of daily chemicals and cosmetics: Focus on market demand, establish an all-channel marketing system, and expand customer channels - Innovation-driven development: Focus on new drug research and development, clinical value-oriented research, and transformation of scientific and technological achievements - Strengthening corporate governance: Optimize corporate governance structure, improve corporate system construction, and enhance governance level